Clinical Trial Search

Primary: Number of Patients With Objective Responses (Complete, Major, Moderate or Minor Responses), in Terms of Best Overall Response — 2; 12; 2; 1 Participants

Primary: Association of Percentage of Mean Residual Expression (MRE%) of NFAT-related Cytokine Expression and Acute Cellular Rejection — 39.5; 41.7 percentage of mean residual…

Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score After 12 Days of Treatment — 21.0; 17.2 units on a scale

Primary: Mean Central Subfield Thickness (CST) — 422.9; 419.7; 364.5; 346.7 microns

Primary: Aberrant Behavior Checklist (ABC) - Parent Reported Change — -2.4 score on a scale — p=0.56

Primary: Change in ADHD Rating Scale (ADHD-RS) Total Score — -14.2; -13.8 units on a scale

Primary: Area Under the Receiver Operating Characteristic (ROC) Curve- Groundskeeper Game — 0.78 Proportion of accurate ADHD Diagnoses

Primary: Headache Recurrence at 48 Hours — 1; 1 Participants

Primary: Visual Ability (VA) — 0.91; 0.87 units on a scale (LogMAR) — p=0.065

Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan in Each Period — 233; 227 nanogram per milliliter (ng/mL)

Primary: Hostile Thoughts on the Articulated Thoughts in Simulated Situations Task — 8.00; 7.62; 4.36; 4.23 score on a scale — p=>.10

Primary: Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation — 0.90 percentage of times value is true

Primary: Changes in Osteoporosis Knowledge, Self-efficacy/Outcome Expectations for Calcium Intake and Exercise, Health Behaviors (Calcium Intake, Exercise) — 19.8; 19.3; 16.7…

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) During Advate Treatment Period — 2; 1; 1; 0…

Primary: Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) — 259; 293 nanogram per milliliter (ng/mL)